Evogene (EVGN) Director Recanati Buys 800,000 Shares

What Happened Leon Recanati, a director of Evogene Ltd. (EVGN), purchased 800,000 ordinary shares in open-market transactions on August 4, 2026. The reported weighted-average price was $0.50 per share, for a total reported cost of approximately $400,000. This was a purchase (a bullish signal in that cash was spent to acquire stock), not a sale or option exercise.

Key Details

• Transaction date: August 4, 2026 (reported on Form 4 filed August 5, 2026) — filing appears timely.
• Transaction type/code: P = Purchase (open market/private purchase).
• Shares purchased: 800,000 at a weighted-average price of $0.50; total value ≈ $400,000.
• Price note (F1): $0.50 is a weighted average; purchases occurred in multiple trades at varying prices on Aug 4; the reporting person will provide breakdowns on request.
• Holdings after transaction: Not specified in the provided summary of the filing (the Form 4 includes an informational row noted by footnote F2).
• Other remarks: Filing includes Exhibit 24.1 (Power of Attorney). Footnote F3 regarding option vesting appears in the filing but is unrelated to this purchase row.

Context For retail investors, insider purchases like this show the director acquired stock with personal funds, which can be viewed as a direct investment in the company. The filing is factual and does not disclose the director’s motivation. If you need the exact per-trade prices or updated post-transaction holdings, the filer has offered to supply full trade-level details upon request (per F1).